Exchange: NASDAQ·Updated 04:35 PM EST
CGEM logo

CGEM Cullinan Oncology Inc

$9.06
$0.18
(1.99%)
Today
Closed $8.89
$0.17
(1.91%)
After Hours
Reported EarningsNov 10
Mkt Cap$588.83M
Vol1.01M

About CGEM

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
39

Bearish Sentiment

How do you feel about CGEM?

metalcook
$CGEM back in cgem at 8.5... 3 chances to get back to 20s soon 1) improved data at ASH for CLN-049 around 13 Dec 2026 2) good data of CLN-948 in RA around 15 Dec 2026 3) Early approval of Zipalertinib in second line which will probably lead to selling off the asset to Tahio.
1
Rayvio_News_Filter
$CGEM · $RAIN 🏥 Cullinan Therapeutics, Inc. announced that its partner Taiho Oncology, Inc. completed a New Drug Application submission to the FDA for zipalertinib plus platinum-based chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung cancer, based on Phase 3 REZILIENT3 data.
1
AlertsAndNews
$CGEM Early data here. Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 "Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses"
1
JFais
$CGEM down another 20% on disappointing FLT3 update (ORR and CR rates came down). Lucky exit prior, had this one on my "bait and switch" watchlist for possible revisit but losing interest here
1
theBigDollarski
$CGEM this stock has lost 50% since announcement of NDA....so what gives?? I hate the boiler room types.
dcrown
$CGEM Cullinan's updated 21% composite complete response (cCR) and 45% overall response rate (ORR) drop from a ~31% remission rate down to ~21% disappointed institutional investors
theBigDollarski
$CGEM for refractory AML patients what is the current standard of care...or is there one?? I am sure its pretty dismal compared to the results.
Merlintrader
$CGEM — Velinotamig: FDA and Australia cleared Phase 1b/2a in ITP and wAIHA. Information only — not investment advice. More details in our hub.
Rayvio_News_Filter
$CGEM 🏥 Cullinan Therapeutics received U.S. FDA and Australian TGA clearance to initiate a Phase 1b/2a study of Velinotamig in relapsing/refractory ITP and warm autoimmune hemolytic anemia.

Advertisement|Remove ads.